Pyrotinib
Top HER2-positive breast cancer news from SABCS
San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.
Novel agent ‘highly efficient’ in HER2-positive breast cancer
SAN ANTONIO — The novel antibody-drug conjugate SHR-A1811 exhibited promising antitumor activity as neoadjuvant treatment for patients with HER2-positive breast cancer, according to data presented at San Antonio Breast Cancer Symposium.
Pyrotinib regimen improves PFS in HER2-positive metastatic breast cancer
SAN ANTONIO — The addition of pyrotinib to first-line trastuzumab and docetaxel improved PFS among patients with HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.
Pyrotinib plus chemotherapy may benefit patients with pretreated HER2-positive breast cancer
Pyrotinib plus capecitabine prolonged OS and PFS compared with lapatinib-capecitabine among patients with pretreated HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.